Self-reported hepatitis C virus antibody status and risk behavior in young injectors

Holly Hagan, Jennifer Campbell, Hanne Thiede, Steffanie Strathdee, Lawrence Ouellet, Farzana Kapadia, Sharon Hudson, Richard S. Garfein

Research output: Contribution to journalArticle

Abstract

Objective. This study was conducted to assess the accuracy of self-reported hepatitis C virus (HCV) antibody (anti-HCV) serostatus in injection drug users (IDUs), and examine whether self-reported anti-HCV serostatus was associated with recent injection risk behavior. Methods. In five U.S. cities (Baltimore, Chicago, Los Angeles, New York, and Seattle), 3,004 IDUs from 15 to 30 years old were recruited for a baseline interview to determine eligibility for a randomized controlled trial of a behavioral intervention. HIV and HCV antibody testing were performed, and subject data (e.g., demographics, drug and sexual risk behavior, and history of HIV and HCV testing) were collected via audio computer-administered self-interview. Risk behavior during the previous three months was compared to self-reported anti-HCV serostatus. Results. Anti-HCV prevalence in this sample of young IDUs was 34.1%. Seventy-two percent of anti-HCV-positive and 46% of anti-HCV-negative IDUs in this sample were not aware of their HCV serostatus. Drug treatment or needle exchange use was associated with increased awareness of HCV serostatus. Anti-HCV-negative IDUs who knew their serostatus were less likely than those unaware of their status to inject with a syringe used by another IDU or to share cottons to filter drug solutions. Knowledge of one's positive anti-HCV status was not associated with safer injection practices. Conclusions. Few anti-HCV-positive IDUs in this study were aware of their serostatus. Expanded availability of HCV screening with high quality counseling is clearly needed for this population to promote the health of chronically HCV-infected IDUs and to decrease risk among injectors susceptible to acquiring or transmitting HCV.

Original languageEnglish (US)
Pages (from-to)710-719
Number of pages10
JournalPublic Health Reports
Volume121
Issue number6
StatePublished - Nov 2006

Fingerprint

Hepatitis C Antibodies
Risk-Taking
Hepacivirus
Drug Users
Injections
HIV
Pharmaceutical Preparations
Interviews
Baltimore
Los Angeles
Syringes
Sexual Behavior
Needles
Counseling

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Hagan, H., Campbell, J., Thiede, H., Strathdee, S., Ouellet, L., Kapadia, F., ... Garfein, R. S. (2006). Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Reports, 121(6), 710-719.

Self-reported hepatitis C virus antibody status and risk behavior in young injectors. / Hagan, Holly; Campbell, Jennifer; Thiede, Hanne; Strathdee, Steffanie; Ouellet, Lawrence; Kapadia, Farzana; Hudson, Sharon; Garfein, Richard S.

In: Public Health Reports, Vol. 121, No. 6, 11.2006, p. 710-719.

Research output: Contribution to journalArticle

Hagan, H, Campbell, J, Thiede, H, Strathdee, S, Ouellet, L, Kapadia, F, Hudson, S & Garfein, RS 2006, 'Self-reported hepatitis C virus antibody status and risk behavior in young injectors', Public Health Reports, vol. 121, no. 6, pp. 710-719.
Hagan H, Campbell J, Thiede H, Strathdee S, Ouellet L, Kapadia F et al. Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Reports. 2006 Nov;121(6):710-719.
Hagan, Holly ; Campbell, Jennifer ; Thiede, Hanne ; Strathdee, Steffanie ; Ouellet, Lawrence ; Kapadia, Farzana ; Hudson, Sharon ; Garfein, Richard S. / Self-reported hepatitis C virus antibody status and risk behavior in young injectors. In: Public Health Reports. 2006 ; Vol. 121, No. 6. pp. 710-719.
@article{79b64e2b1b0f478eacb538b7223142b7,
title = "Self-reported hepatitis C virus antibody status and risk behavior in young injectors",
abstract = "Objective. This study was conducted to assess the accuracy of self-reported hepatitis C virus (HCV) antibody (anti-HCV) serostatus in injection drug users (IDUs), and examine whether self-reported anti-HCV serostatus was associated with recent injection risk behavior. Methods. In five U.S. cities (Baltimore, Chicago, Los Angeles, New York, and Seattle), 3,004 IDUs from 15 to 30 years old were recruited for a baseline interview to determine eligibility for a randomized controlled trial of a behavioral intervention. HIV and HCV antibody testing were performed, and subject data (e.g., demographics, drug and sexual risk behavior, and history of HIV and HCV testing) were collected via audio computer-administered self-interview. Risk behavior during the previous three months was compared to self-reported anti-HCV serostatus. Results. Anti-HCV prevalence in this sample of young IDUs was 34.1{\%}. Seventy-two percent of anti-HCV-positive and 46{\%} of anti-HCV-negative IDUs in this sample were not aware of their HCV serostatus. Drug treatment or needle exchange use was associated with increased awareness of HCV serostatus. Anti-HCV-negative IDUs who knew their serostatus were less likely than those unaware of their status to inject with a syringe used by another IDU or to share cottons to filter drug solutions. Knowledge of one's positive anti-HCV status was not associated with safer injection practices. Conclusions. Few anti-HCV-positive IDUs in this study were aware of their serostatus. Expanded availability of HCV screening with high quality counseling is clearly needed for this population to promote the health of chronically HCV-infected IDUs and to decrease risk among injectors susceptible to acquiring or transmitting HCV.",
author = "Holly Hagan and Jennifer Campbell and Hanne Thiede and Steffanie Strathdee and Lawrence Ouellet and Farzana Kapadia and Sharon Hudson and Garfein, {Richard S.}",
year = "2006",
month = "11",
language = "English (US)",
volume = "121",
pages = "710--719",
journal = "Public Health Reports",
issn = "0033-3549",
publisher = "Association of Schools of Public Health",
number = "6",

}

TY - JOUR

T1 - Self-reported hepatitis C virus antibody status and risk behavior in young injectors

AU - Hagan, Holly

AU - Campbell, Jennifer

AU - Thiede, Hanne

AU - Strathdee, Steffanie

AU - Ouellet, Lawrence

AU - Kapadia, Farzana

AU - Hudson, Sharon

AU - Garfein, Richard S.

PY - 2006/11

Y1 - 2006/11

N2 - Objective. This study was conducted to assess the accuracy of self-reported hepatitis C virus (HCV) antibody (anti-HCV) serostatus in injection drug users (IDUs), and examine whether self-reported anti-HCV serostatus was associated with recent injection risk behavior. Methods. In five U.S. cities (Baltimore, Chicago, Los Angeles, New York, and Seattle), 3,004 IDUs from 15 to 30 years old were recruited for a baseline interview to determine eligibility for a randomized controlled trial of a behavioral intervention. HIV and HCV antibody testing were performed, and subject data (e.g., demographics, drug and sexual risk behavior, and history of HIV and HCV testing) were collected via audio computer-administered self-interview. Risk behavior during the previous three months was compared to self-reported anti-HCV serostatus. Results. Anti-HCV prevalence in this sample of young IDUs was 34.1%. Seventy-two percent of anti-HCV-positive and 46% of anti-HCV-negative IDUs in this sample were not aware of their HCV serostatus. Drug treatment or needle exchange use was associated with increased awareness of HCV serostatus. Anti-HCV-negative IDUs who knew their serostatus were less likely than those unaware of their status to inject with a syringe used by another IDU or to share cottons to filter drug solutions. Knowledge of one's positive anti-HCV status was not associated with safer injection practices. Conclusions. Few anti-HCV-positive IDUs in this study were aware of their serostatus. Expanded availability of HCV screening with high quality counseling is clearly needed for this population to promote the health of chronically HCV-infected IDUs and to decrease risk among injectors susceptible to acquiring or transmitting HCV.

AB - Objective. This study was conducted to assess the accuracy of self-reported hepatitis C virus (HCV) antibody (anti-HCV) serostatus in injection drug users (IDUs), and examine whether self-reported anti-HCV serostatus was associated with recent injection risk behavior. Methods. In five U.S. cities (Baltimore, Chicago, Los Angeles, New York, and Seattle), 3,004 IDUs from 15 to 30 years old were recruited for a baseline interview to determine eligibility for a randomized controlled trial of a behavioral intervention. HIV and HCV antibody testing were performed, and subject data (e.g., demographics, drug and sexual risk behavior, and history of HIV and HCV testing) were collected via audio computer-administered self-interview. Risk behavior during the previous three months was compared to self-reported anti-HCV serostatus. Results. Anti-HCV prevalence in this sample of young IDUs was 34.1%. Seventy-two percent of anti-HCV-positive and 46% of anti-HCV-negative IDUs in this sample were not aware of their HCV serostatus. Drug treatment or needle exchange use was associated with increased awareness of HCV serostatus. Anti-HCV-negative IDUs who knew their serostatus were less likely than those unaware of their status to inject with a syringe used by another IDU or to share cottons to filter drug solutions. Knowledge of one's positive anti-HCV status was not associated with safer injection practices. Conclusions. Few anti-HCV-positive IDUs in this study were aware of their serostatus. Expanded availability of HCV screening with high quality counseling is clearly needed for this population to promote the health of chronically HCV-infected IDUs and to decrease risk among injectors susceptible to acquiring or transmitting HCV.

UR - http://www.scopus.com/inward/record.url?scp=33846457516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846457516&partnerID=8YFLogxK

M3 - Article

C2 - 17278406

AN - SCOPUS:33846457516

VL - 121

SP - 710

EP - 719

JO - Public Health Reports

JF - Public Health Reports

SN - 0033-3549

IS - 6

ER -